Keyphrases
Abatacept
12%
Acute Myeloid Leukemia
9%
Alemtuzumab
25%
Allogeneic
9%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
36%
Allogeneic Peripheral Blood Stem Cell Transplantation
10%
Allogeneic Transplantation
11%
Bone Marrow Transplantation
10%
Cell Therapy
11%
Chimerism
10%
Clinical Trials Network
9%
Conditioning Regimen
14%
Disease-free Survival
9%
Donor chimerism
12%
Engraftment
15%
Event-free Survival
11%
Fludarabine
15%
Graft Rejection
16%
Graft-versus-host Disease (GvHD)
73%
Granulocyte Colony-stimulating Factor (G-CSF)
9%
Haploidentical Transplantation
11%
Hematopoietic Cell Transplant
13%
Hematopoietic Cell Transplantation
70%
Hematopoietic Stem Cell Transplantation
48%
Hemoglobinopathies
13%
High Risk
18%
HLA-matched Donor
13%
Immune Reconstitution
17%
Late Effects
12%
Living Donor
11%
Malignant Disorders
21%
Marrow
9%
Marrow Transplantation
28%
Melphalan
12%
Mismatched Related Donor
9%
Overall Survival
11%
Pediatric
21%
Pediatric Patients
18%
Peripheral Blood Stem Cell Transplantation
9%
Preparative Regimen
9%
Primary Immune Deficiency
9%
Reduced Intensity
12%
Reduced-intensity Conditioning
41%
Sickle Cell Disease
100%
Stem Cell Source
9%
Stem Cell Transplantation
35%
Transplantation
44%
Umbilical Cord Blood
15%
Unrelated Donor
36%
Unrelated Donor Transplantation
23%
Medicine and Dentistry
Acute Graft Versus Host Disease
7%
Acute Myeloid Leukemia
6%
Alemtuzumab
9%
Allogeneic Hematopoietic Stem Cell Transplantation
8%
Allograft
8%
Apoplexy
8%
Autoimmunity
11%
B Cell
9%
Cancer
6%
Cell Therapy
11%
Cell Transplantation
64%
Chronic Graft Versus Host Disease
7%
Clinical Trial
14%
Conditioning
23%
Cord Blood
16%
Disease
24%
Diseases
35%
Engraftment
15%
Event Free Survival
12%
Fludarabine
7%
Graft Failure
8%
Graft Rejection
10%
Graft Versus Host Reaction
32%
Granulocyte Colony Stimulating Factor
6%
Granulocyte Transfusion
8%
Hematologic Malignancy
7%
Hematopoietic Cell
71%
Hematopoietic Stem Cell Transplantation
45%
Hemoglobinopathy
13%
Immune Deficiency
7%
Immune Reconstitution
7%
Immunosuppressive Treatment
8%
Late Effect
11%
Myelodysplastic Syndrome
8%
Neutrophil
6%
Overall Survival
9%
Patient with Sickle Cell Disease
13%
Pediatrics
33%
Pediatrics Patient
10%
Peripheral Blood Stem Cell
8%
Quality of Life
8%
Reduced Intensity Conditioning
22%
Rituximab
9%
Sickle-Cell Disease
78%
Stem Cell
8%
Stem Cell Therapy
32%
Stem Cell Transplant
9%
T Cell
6%
Thalassemia
9%
Thalassemia Major
6%
Immunology and Microbiology
Abatacept
10%
Acute Graft Versus Host Disease
16%
Alemtuzumab
22%
Allogeneic Peripheral Blood Stem Cell Transplantation
11%
Allograft
11%
Autoimmune Lymphoproliferative Syndrome
6%
Autoimmunity
11%
B Cell
8%
Bone Marrow Transplantation
5%
CD34
8%
CD4
5%
Cell Transplantation
60%
Chronic Graft Versus Host Disease
22%
Chronic Granulomatous Disease
5%
Comorbidity
6%
Conditioning
43%
Cord Blood Stem Cell Transplantation
5%
Cyclophosphamide
5%
Disease Free Survival
9%
Engraftment
26%
Event Free Survival
7%
Graft-Versus-Host Disease
53%
Granulocyte
5%
Granulocyte Colony-Stimulating Factor
7%
Hematopoietic Cell
64%
Hematopoietic Stem Cell Transplantation
30%
Hemoglobin
6%
Hemophagocytic Lymphohistiocytosis
5%
Human Leukocyte Antigen
5%
Hydroxychloroquine
5%
Immune Reconstitution
14%
Immunodeficiency
12%
Lymphocyte
8%
Methotrexate
8%
Myeloid
8%
Neutrophil
10%
Overall Survival
10%
Peripheral Blood Stem Cell
16%
Platelet
8%
Regulatory T Cell
6%
Rituximab
8%
Severe Combined Immunodeficiency
5%
Sickle Cell
50%
Stem Cell
14%
Stem Cell Transplant
17%
Stem Cell Transplantation
14%
T Cell
10%
Umbilical Cord Blood
9%
